Medjet aims to offer alternative to laser in vision correction
This article was originally published in Clinica
With its waterjet keratome, Medjet is hoping to market a device which will be a serious competitor to lasers in the correction of vision deficiencies. The development-stage company, based in Edison, New Jersey, intends to seek US FDA approval for hydro-therapeutic keratoplasty first, followed by a submission for hydro-refractive keratoplasty. In its prospectus for a recent public offering, the company considers that the device will only have to pass a 510(k) approval for both procedures.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.